Somewhat Positive News Coverage Somewhat Unlikely to Impact Zoetis (ZTS) Share Price
Press coverage about Zoetis (NYSE:ZTS) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zoetis earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.8196789630085 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Investors In Zoetis Inc (NYSE:ZTS) Are Paying Above The Intrinsic Value (finance.yahoo.com)
- Zoetis (ZTS) Price Target Increased to $78.00 by Analysts at BMO Capital Markets (americanbankingnews.com)
- Zoetis (ZTS) Rating Reiterated by BMO Capital Markets (americanbankingnews.com)
- Zoetis (ZTS) Downgraded by Zacks Investment Research to Hold (americanbankingnews.com)
- Zevenbergen Capital Investments Has Increased Zoetis (ZTS) Position; SHISEIDO COMPANY LTD ORD (SSDOF … – Hill Country Times (hillcountrytimes.com)
A number of research firms recently issued reports on ZTS. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Thursday, October 12th. BidaskClub downgraded shares of Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. BMO Capital Markets raised their price objective on shares of Zoetis to $78.00 and gave the stock a “market perform” rating in a report on Tuesday. Craig Hallum restated a “buy” rating and set a $85.00 price objective (up previously from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Finally, Cantor Fitzgerald set a $85.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $71.28.
Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The company’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the business earned $0.52 earnings per share. sell-side analysts expect that Zoetis will post 2.37 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Thursday, January 18th. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio (DPR) is currently 22.11%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.